RxSight (RXST) Q4 2025 earnings review
Strategy Pivot Fails to Ignite Growth as 2026 Outlook Disappoints
RxSight's strategic pivot away from capital equipment sales toward driving LAL utilization within its existing installed base has hit a wall. While management highlighted a 10% sequential increase in LAL procedures and 'early signs of progress,' the year-over-year metrics tell a sobering story: Q4 LAL unit sales reversed into negative territory (-2%), and total revenue fell 19%. More concerning is the 2026 guidance, which forecasts further revenue contraction at the midpoint and a severe reversal in gross margin. The collapse in Light Delivery Device (LDD) placements is now creating a dual headwind: starving the company of future consumable growth while crushing factory overhead absorption.
🐂 Bull Case
The company ended the year with $228.1M in cash, cash equivalents, and short-term investments, providing significant runway to execute the commercial turnaround without immediate dilution risk.
LAL procedures grew 10% sequentially in Q4 (to 28,611 units) compared to Q3. This suggests that the unified 'Customer Success' organization deployed in H2 2025 is generating some seasonal traction within the installed base of 1,134 LDDs.
🐻 Bear Case
The entire strategic pivot relies on increasing LAL volume in existing accounts. Yet, LAL unit sales contracted 2% YoY in Q4. If the active installed base cannot generate YoY procedure growth, the business model is structurally flawed.
The 70% YoY drop in Q4 LDD placements is destroying production leverage. Management explicitly cited higher per-unit manufacturing costs from lower LDD volumes as the driver for a 500+ bps margin compression guided for 2026.
⚖️ Verdict: 🔴
Bearish. The company is actively shrinking. Operating expenses are rising against a decelerating top line, the flagship consumable product has stopped growing year-over-year, and 2026 guidance offers no structural inflection point.
Key Themes
LAL Consumable Growth Reverses to Contraction
The most alarming data point in the Q4 report is the -2% YoY print for Light Adjustable Lens (LAL) unit sales (28,611 units). Throughout 2025, YoY growth decelerated dramatically: 36% (Q1) → 13% (Q2) → 6% (Q3) → -2% (Q4). Because management intentionally suppressed new capital placements (LDDs) to focus field teams entirely on LAL utilization, this contraction indicates that same-store sales dynamics are heavily impaired.
Gross Margin Reversing Due to Unabsorbed Overhead
In Q3, RxSight boasted a 79.9% gross margin due to a favorable mix shift toward high-margin LALs. Q4 remained healthy at 77.5%. However, 2026 guidance reverses this trend entirely, projecting 70%-72% margins. Management explicitly blamed this on 'higher per-unit manufacturing costs associated with lower LDD production volumes.' The prolonged pause in capital sales is now cannibalizing the profitability of the overall business.
LDD Placements Have Bottomed Out
The company sold exactly 25 Light Delivery Devices in Q4, completely flat QoQ vs Q3, and down 70% YoY. The installed base now stands at 1,134. While stable sequentially, the historically low placement volume severely limits the funnel for new surgeon adoption heading into 2026.
International Approvals Paving a Long-Term Runway
RxSight announced regulatory approval in Australia in Q4. This adds to recent approvals in Europe (CE Mark), Singapore, and South Korea. While management has previously stated international expansion will be methodical and slow to contribute materially to revenue, it provides an essential growth valve as the U.S. market wrestles with utilization bottlenecks.
Other KPIs
Accelerating against a shrinking top line. OpEx grew 11% YoY for the full year, driven by the structural realignment of the commercial team in H2 2025. This negative operating leverage drove the full-year net loss to expand from $27.5M in 2024 to $38.9M in 2025.
Reversing from an adjusted net gain of $1.3M in 24Q4. Excluding $7.8M in stock-based compensation, the core business swung back to an adjusted loss in the fourth quarter, primarily driven by the $7.6M YoY revenue shortfall.
Guidance
Decelerating. The midpoint of $127.5M implies a 5.2% decline versus FY25 revenue of $134.5M. This signals management does not expect the LAL utilization initiatives to offset the continued drag from depressed LDD capital placements in the upcoming year.
Reversing. A sharp drop from the 76.6% achieved in FY25, driven entirely by the loss of manufacturing scale on the capital equipment side of the business.
Stable compared to FY25's $151.2M. While the company is holding the line on absolute expense growth, the forecasted decline in revenue and gross margin means operating losses will likely expand significantly in 2026.
Key Questions
Path Back to LAL Growth
Despite dedicating the field force entirely to customer success and utilization in H2 2025, Q4 LAL units fell 2% YoY. If the installed base of 1,134 LDDs cannot generate organic year-over-year growth, what structural changes are required in 2026 to break the stagnation?
Cash Flow Breakeven Timeline
With gross margins compressing to the low 70s and revenue expected to decline at the midpoint next year, how far out has the internal target for cash flow breakeven been pushed, and at what point does the current $228M cash position require bolstering?
Capital Equipment Strategy
Selling only 25 LDDs a quarter is resulting in unabsorbed manufacturing overhead that is destroying gross margins. Is there a strategic plan to reignite capital placements, or is 25-30 units the new quarterly baseline moving forward?